The one-sentence answer
Pharmac decides which medicines the public health system subsidises; private health insurance mostly pays for elective surgery, private-hospital care and faster specialist access. One is about drug funding; the other is about where and how fast you get treated. Some private policies also add cover for specific medicines Pharmac does not fund.
What Pharmac is — and what it is not
Pharmac (the Pharmaceutical Management Agency) is the Crown agency that decides which medicines and related products are publicly funded in New Zealand. The funded list is the Pharmaceutical Schedule. If a medicine is on the Schedule and you meet the funding criteria, the public system subsidises it — regardless of whether you hold private health insurance.
Pharmac does not pay for elective surgery, private-hospital stays, or private specialist consultations. It is a medicines-funding agency, not a treatment or hospital funder. The hospitals, emergency care and public elective services themselves are run by Te Whatu Ora — Health New Zealand.
What "non-Pharmac" means
A "non-Pharmac" medicine is one that is not on the Pharmaceutical Schedule — so it is not publicly subsidised. A medicine can be approved as safe and effective for use in New Zealand by Medsafe (the safety regulator) and still not be funded by Pharmac. Several high-profile cancer medicines have sat in this gap: Medsafe-approved but not Pharmac-funded, leaving the patient to pay privately unless another arrangement covers the cost. This is the gap private health insurance can sometimes fill.
Where private health insurance fits
Private health insurance in New Zealand is bought mainly to:
- access elective (planned) surgery in private hospitals, reducing time on public elective waiting lists;
- get faster specialist consultations and diagnostics; and
- on some policies, cover specific non-Pharmac medicines (most commonly certain non-funded, Medsafe-indicated cancer drugs) up to a per-product annual cap.
It generally does not cover accident-related treatment that ACC already pays for, acute emergency care (a public-system function), or routine medicines that Pharmac already funds. See our ACC interaction topic for how policies handle ACC overlap.
How NZ insurers treat Pharmac vs non-Pharmac drugs (from the wordings)
Across the active retail products in our data layer, 23 document a Pharmac-related drug rule and 18 document a high-cost cancer-drug benefit. A common pattern is: the everyday prescription-drug benefit is limited to Pharmac-funded medicines, while a separate oncology benefit covers certain non-Pharmac, Medsafe-indicated chemotherapy drugs up to a stated annual cap that differs by product. Because the exact rule varies by benefit and product, we publish each insurer's clause verbatim rather than summarising it:
- Pharmac vs non-Pharmac drug cover — every product's rule, verbatim
- Oncology & high-cost cancer drugs — per-product cover
- NZ health insurance coverage study — the data behind these figures
Common misconceptions
- "Pharmac and private insurance are alternatives." They are not — Pharmac funds medicines through the public system; private insurance funds private treatment. You can rely on both at once.
- "If a drug is Medsafe-approved, it's funded." No. Medsafe approval (safety/efficacy) and Pharmac funding (public subsidy) are separate decisions.
- "My health insurance covers all my prescriptions." Most policies cap or restrict everyday prescription cover, and several limit it to Pharmac-funded medicines — check the wording.